Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Mid-Stabilisation Period Announcement

20 Mar 2017 07:00

RNS Number : 8801Z
Arix Bioscience Plc
20 March 2017
 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTIONS WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

20th March 2017

Mid-Stabilisation Period Announcement

Arix Bioscience Plc (the "Company")

Further to the pre-stabilisation period announcement dated 17th February 2017, Jefferies International Limited (contact: Luca Erpici +44 (0)20 7029 8415; Lee Morton +44 (0)20 7029 8753) hereby gives notice that the Stabilisation manager named below undertook stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in relation to the offer of the following securities, as set out below:

 

Issuer:

Arix Bioscience Plc

Securities:

Ordinary Shares (ISIN: GB00BD045071)

Offering Size:

48,309,179 Ordinary shares excluding the over-allotment option

Offer Price:

207p per ordinary share

Market:

London Stock Exchange, Over-The-Counter (OTC) and other order book venues e.g. Turquoise, BATS and Chi-X

Ticker:

ARIX

Stabilising Manager:

Jefferies International Limited

 

Stabilisation Transactions:

Date of Execution

Time of Execution (GMT)

Quantity

Price

Execution Venue

13/03/2017

11:24:39

25,000

207

London Stock Exchange

13/03/2017

12:12:30

10,000

207

London Stock Exchange

16/03/2017

08:08:43

50

207

London Stock Exchange

16/03/2017

08:08:43

25,000

207

London Stock Exchange

16/03/2017

08:18:36

600

207

London Stock Exchange

16/03/2017

08:18:36

600

207

London Stock Exchange

16/03/2017

08:18:36

25,000

207

London Stock Exchange

16/03/2017

08:46:40

600

207

London Stock Exchange

16/03/2017

08:46:40

600

207

London Stock Exchange

16/03/2017

08:46:40

600

207

London Stock Exchange

16/03/2017

08:46:40

600

207

Chi-X

16/03/2017

08:46:40

600

207

Chi-X

16/03/2017

08:47:33

779

206

London Stock Exchange

16/03/2017

08:54:17

440

207

Turquoise

16/03/2017

08:54:17

160

207

BATS

16/03/2017

08:58:20

280

207

BATS

16/03/2017

08:58:20

320

207

Turquoise

16/03/2017

09:01:52

120

207

Turquoise

16/03/2017

09:01:52

440

207

BATS

16/03/2017

09:01:52

40

207

London Stock Exchange

16/03/2017

09:15:57

440

207

Turquoise

16/03/2017

09:15:57

160

207

BATS

16/03/2017

09:17:58

280

207

BATS

16/03/2017

09:17:58

320

207

London Stock Exchange

16/03/2017

09:31:38

600

207

London Stock Exchange

16/03/2017

09:34:25

600

207

London Stock Exchange

16/03/2017

09:36:41

600

207

London Stock Exchange

16/03/2017

09:51:24

600

207

London Stock Exchange

16/03/2017

09:53:52

600

207

London Stock Exchange

16/03/2017

09:55:34

600

206.5

London Stock Exchange

16/03/2017

10:08:50

380

207

London Stock Exchange

16/03/2017

10:08:50

220

207

London Stock Exchange

16/03/2017

10:19:30

600

207

London Stock Exchange

16/03/2017

10:26:13

600

207

London Stock Exchange

16/03/2017

10:28:33

538

207

London Stock Exchange

16/03/2017

10:28:33

62

207

London Stock Exchange

16/03/2017

10:41:06

600

207

London Stock Exchange

16/03/2017

10:45:25

600

207

London Stock Exchange

16/03/2017

10:57:41

538

207

London Stock Exchange

16/03/2017

11:32:46

600

207

London Stock Exchange

16/03/2017

11:32:46

600

207

London Stock Exchange

16/03/2017

11:32:46

600

207

London Stock Exchange

16/03/2017

11:33:52

600

207

London Stock Exchange

16/03/2017

11:37:41

600

207

London Stock Exchange

16/03/2017

11:51:23

600

207

London Stock Exchange

16/03/2017

11:54:13

600

207

London Stock Exchange

16/03/2017

12:10:02

600

207

London Stock Exchange

16/03/2017

12:20:09

600

207

London Stock Exchange

16/03/2017

12:27:10

600

207

London Stock Exchange

16/03/2017

12:37:31

600

207

London Stock Exchange

16/03/2017

12:45:17

7

207

London Stock Exchange

16/03/2017

12:45:17

593

207

London Stock Exchange

16/03/2017

12:55:01

7

207

London Stock Exchange

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:42

600

207

Chi-X

16/03/2017

15:17:46

462

207

Chi-X

16/03/2017

15:17:46

600

207

Chi-X

16/03/2017

15:17:46

600

207

Chi-X

16/03/2017

15:17:46

600

207

Chi-X

17/03/2017

09:08:03

2325

207

London Stock Exchange

 

Disclaimer:

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

This announcement and copies of this announcement are not being made and may not be distributed, published, or sent, directly or indirectly, in whole or in part, in or into the United States, Australia, Canada, South Africa or Japan or to any persons in any of those jurisdictions or any other jurisdictions where to do so would be unlawful or would require registration or other measures. The release, publication or distribution of this announcement in other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions.

The Offer and the distribution of this announcement and other information in connection with the listing and Offer in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement is not and does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase any securities in the United States, Australia, Canada, Japan, South Africa or any other jurisdiction where such an offer would be unlawful.

The Securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable laws of any state or other jurisdiction of the United States. The securities are being offered and sold outside the United States in offshore transactions as defined in, and in compliance with, Regulation S under the US Securities Act or within the United States only to "Qualified Institutional Buyers" ("QIBS") as defined in Rule 144A under the US Securities Act ("Rule 144"), who are also, in each case, "Qualified Purchasers" ("QPs"), as defined in section 2(a)(51) of the Investment Act of 1940, as amended (the "Investment Company Act"), or pursuant to another exemption form, or in a transaction not subject to, the registration requirements of the US Securities Act. Any forwarding, distribution or reproduction of this announcement, the publication in which it is contained and any copy of it in whole or in part is unauthorised. Failure to comply with this notice may result in a violation of the US Securities Act or the applicable laws or other jurisdictions. This announcement does not contain or constitute an offer to buy or subscribe for, the securities referred to herein to any person in any jurisdiction where it is unlawful to do so. The Company does not intend to register any part of the Offer in the United States and there will be no public offering of securities in the United States.

The Securities have not been and will not be registered under the applicable securities laws of Canada, Japan, South Africa or Australia and may not be offered or sold in Canada, Japan, South Africa or Australia except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the applicable securities laws. There will be no public offering of securities in Canada, Japan, South Africa or Australia.

This announcement is only addressed to, and directed at, persons in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive ("Qualified Investors"). For the purposes of this provision, the expression "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each member state of the European Economic Area which has implemented the Prospectus Directive. In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments who fall within the definition of "investment professional" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) who are high net worth companies, unincorporated associations and partnerships and trustees of high value trusts or other persons to whom it may otherwise lawfully be communicated falling within Article 49(2)(a)-(d) of the Order, (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this announcement relates is available only to and will only be engaged in with such persons. This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons; and (ii) in any member state of the European Economic Area other than the United Kingdom, by persons who are not Qualified Investors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STADXGDXRSBBGRC
Date   Source Headline
16th Mar 20237:01 amEQSUnaudited NAV for February 2023
14th Feb 20236:19 pmEQSPortfolio company Disc Medicine announces $62.5 million financing
6th Feb 20236:00 pmEQSDirector/PDMR Shareholding
6th Feb 20235:00 pmEQSDirector/PDMR Shareholding
6th Feb 20238:00 amEQSUnaudited NAV for January 2023
6th Feb 20237:00 amEQSUnaudited NAV for January 2023
30th Jan 20238:00 amEQSUnaudited NAV for December 2022
30th Jan 20237:00 amEQSUnaudited NAV for December 2022
26th Jan 20238:00 amEQSBoard Change
26th Jan 20237:00 amEQSBoard Change
5th Jan 20235:20 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
5th Jan 20234:21 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
30th Dec 20228:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
30th Dec 20227:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
12th Dec 20228:00 amEQSUnaudited NAV for November 2022
12th Dec 20227:01 amEQSUnaudited NAV for November 2022
6th Dec 20228:00 amEQSArix to Present at Mello Investment Trusts & Funds
6th Dec 20227:00 amEQSArix to Present at Mello Investment Trusts & Funds
1st Dec 20227:45 amRNSDirector/PDMR Shareholding
9th Nov 20228:00 amEQSUnaudited NAV for October 2022
9th Nov 20227:00 amEQSUnaudited NAV for October 2022
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
20th Oct 20224:30 pmEQSHolding(s) in Company
20th Oct 20224:30 pmEQSHolding(s) in Company
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
3rd Oct 20224:32 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
3rd Oct 20224:31 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
15th Sep 20227:01 amEQSUnaudited NAV for August 2022
15th Sep 20227:00 amEQSUnaudited NAV for August 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20227:01 amEQSInterim Results for the Six Months Ended 30 June 2022
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:00 amEQSInterim Results for the Six Months Ended 30 June 2022
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jun 20224:45 pmEQSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.